Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the merits of including male veterans and service personnel in the next Men’s Health Strategy.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
On 19 November 2025, to coincide with International Men’s Health Day, we published the first ever Men’s Health Strategy for England. Our vision is to improve the health of all men and boys in England, including male veterans and service personnel.
This strategy is a crucial first step, laying the foundation from which we can learn, iterate and grow to create a society where all men and boys are supported to live longer, healthier and happier lives. As a first step, we will work with the Men's Health Academic Network and the voluntary, community and social enterprise sector to develop and publish a one-year-on report, highlighting the improvements made and where future efforts will need to be targeted.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assistance is available to people who are not sufficiently technologically proficient to use the NHS app.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We are working to improve access to digital services, outcomes, and experiences for the widest range of people, based on their preferences. Digital health tools should be part of a wider offering that includes face-to-face support with appropriate help for people who struggle to access digital services.
Centrally built services, such as the NHS App and National Health Service website, are designed to meet international accessibility standards. We are modernising the mobile patient experience within the NHS App, ensuring information is clearly structured and easy to find and understand.
NHS England has successfully run several programmes to support patients, carers, and health service staff with their digital skills. These include:
the Digital Health Champions programme, a proof of concept to support citizens who have no or low digital skills with understanding how to access health services online;
the Widening Digital Participation programme, aimed to ensure more people have the digital skills, motivation, and means to access health information and services online; and
the NHS App ‘Spoken Word’ Pilot project, designed to test the efficacy of promoting NHS digital health products and services in languages other than English.
We have also recruited over 2,000 NHS App ambassadors and 1,400 libraries to help people to learn how to use the NHS App.
NHS England has published a framework for NHS action on digital inclusion and is developing further resources to support practical actions. All programmes are actively considering how they can contribute to improvements in healthcare inequalities and digital inclusion.
We are also developing a national proxy service to grant authorised access for people to manage health care on behalf of other people that are unable to use the NHS App.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, further to the Written Answer the Minister of State for Care on 5 January (HC99433), whether they have considered allowing local authorities to set or amend the means-testing criteria for the mandatory Disabled Facilities Grant scheme that such authorities administer on behalf of the Government.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In England, we continue to fund the Disabled Facilities Grant (DFG) which is administered by local authorities. This grant helps eligible older and disabled people on low incomes to adapt their homes to make them safe and suitable for their needs. Practical changes include installing stairlifts, level-access showers, and ramps.
As highlighted in the response to HC99433, local authorities already have a significant amount of flexibility in how they deliver the DFG. This includes setting or amending the means-testing criteria.
We have recently announced an additional £50 million for the DFG in 2025/26. This could fund approximately 5,000 home adaptations supporting older and disabled people to live more independently in their homes, it brings the total DFG amount this year to £761 million.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of how the principles of the Armed Forces Covenant are being applied by (1) Op COMMUNITY, and (2) local health bodies.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
No formal assessment has been made to how the principles of the Armed Forces Covenant are being applied by Op COMMUNITY or local health bodies.
Op COMMUNITY was an NHS England funded pilot that concluded in March 2024. Insights from the pilot have been used to shape the new Armed Forces National Training and Education Programme, which aims to strengthen understanding across the National Health Service of the unique needs of the Armed Forces community.
The programme is now being rolled out across the NHS. Dedicated training modules for integrated care boards will be introduced in 2026. These will support local NHS staff in developing a clearer understanding of the specific health needs of the Armed Forces community and the principles underpinning the Armed Forces Covenant.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the cost-effectiveness of increasing the uptake of urine albumin-creatine ratio tests so that all patients with chronic kidney disease have an annual test.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not made a specific assessment. The National Institute for Health and Care Excellence (NICE) is the independent body responsible for providing clinical guidance and quality standards. NICE’s guidance on chronic kidney disease includes guidance on the use of annual urine albumin-creatine ratio tests as the preferred method to detect and monitor kidney disease. The guidance is available on NICE’s website.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether the ranking methodology for the proposed single national formulary will include (1) workforce productivity, (2) equitable patient access, and (3) quality of life outcomes.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The 10-Year Health Plan for England set out a commitment to move towards a Single National Formulary (SNF) for medicines within the next two years. The plan details that the SNF will include sequencing of products within clinical pathways based on clinical and cost effectiveness, overseen by a new formulary oversight board supported by the National Institute for Health and Care Excellence (NICE). NICE guidance will be used for the underpinning clinical and cost effectiveness evidence, including resource implications, to guide these decisions. The SNF will be a key enabler to support fair and equitable patient access to NICE-approved medicines across the country.
Work is already underway to deliver the SNF through a phased approach. We are already working closely and collaboratively with key stakeholders including NICE and the pharmaceutical industry and medical royal colleges, to develop and design the implementation of the SNF. We will continue to utilise local expertise to ensure the SNF is successfully implemented, and local system support, particularly from pharmacy and medicines formulary teams, will be essential to successful delivery of the SNF, which is why joint activity has already started early in the process.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what plans they have to ringfence funding for brain cancer research.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR). Cancer is a major area of NIHR spending at £141.6 million in 2024/25, reflecting its high priority.
Too little is known about how to prevent, diagnose, and manage brain tumours. They remain one of the hardest cancers to treat and a challenging area for research. That is why we are committed to furthering our investment in brain cancer research and have already taken steps to stimulate scientific progress.
In December 2025, the NIHR announced an initial £13.7 million investment in the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. Significant further funding is due to be awarded shortly. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including brain cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality. Welcoming applications on brain cancer to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, what steps they are taking to identify regulatory barriers and evaluate reimbursement policies for brain cancer therapies.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises that there are currently limited treatment options available for people who have been diagnosed with cancerous brain tumours and recognises the significant impact this rare cancer can have on patients, carers, and their families. All new licensed medicines, including medicines for brain cancer, are evaluated by the National Institute for Health and Care Excellence (NICE), which makes recommendations for the National Health Service on whether they represent a clinically and cost effective use of NHS resources. NICE is actively evaluating a number of new medicines for potential use in the treatment of brain cancers.
NICE works closely with companies and the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), and aims to issue guidance on new medicines as close as possible to the time of licensing. The NHS in England is legally required to fund medicines recommended by NICE and funding from the Cancer Drugs Fund is available for cancer medicines from the point of a draft positive NICE recommendation, bringing forward patient access by up to five months.
The MHRA has several pathways which facilitate rapid assessment of medicines. This includes international collaborations such as Project Orbis and the Access Consortium. The MHRA has also introduced the International Recognition Pathway, which allows the MHRA to take into account the expertise and decision-making of trusted regulatory partners, and the Innovative Licensing and Access Pathway scheme, focussed on getting new and transformative medicines to patients in the UK health system more quickly. Recently, the MHRA also issued new regulations to make it faster and easier for cutting-edge cancer treatments and personalised gene therapies to be made right where patients are treated.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the potential impact of reference pricing for drugs on long-term system capacity and the ability of clinicians to tailor treatments to complex patient profiles within ophthalmology services.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
No specific assessment has been made.
The intention of the reference pricing is to support long term capacity in ophthalmology by enabling trusts to reinvest realised savings directly into local services, including workforce, equipment, and service redesign. Clinical autonomy is maintained, and clinicians will continue to be able to tailor treatments to individual patient needs, including complex cases, where this is clinically indicated.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to improve the five-year survival rates for brain cancer.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving outcomes and survival rates remain a firm priority for the Government across all cancer types. However, we recognise that for rarer cancers, such as brain cancers, which are harder to diagnose and treat, survival rates are too low, and this needs to drastically change.
Research is vital in improving survival rates, which is why in December 2025 the National Institute for Health and Care Research (NIHR) announced the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer. The NIHR is investing an initial £13.7 million, with significant further funding due to be awarded early in the new year.
Reducing the number of lives lost to cancer will be a key aim of the National Cancer Plan for England, which is due to be published shortly. The plan will include further details on how we will improve outcomes for cancer patients, including brain cancer patients, as well as speeding up diagnosis and treatment.